Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00411515
Status:
COMPLETED
Last Update Posted:
2006-12-15
First Post:
2006-12-12
Brief Title:
A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty
Sponsor:
University Hospital Freiburg
Organization:
University Hospital Freiburg
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil MMF to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months Endpoints were immune reaction free and clear graft survival and the occurence of side-effects
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months Endpoints were immune reaction free and clear graft survival and the occurence of side-effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None